Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. sophomore Avg
|
|
New words:
Abbott, abridged, Acceleron, accidental, adjacent, ancillary, appeal, argued, arriving, ASLAN, begun, behavior, BeiGene, bidding, billion, bio, bluebird, blueprint, BMS, boost, Brequinar, Cadillac, CAT, chaired, channel, checkpoint, chose, Circuit, compassionate, composed, concession, condensed, constraint, contrary, corridor, credibility, creditworthy, Creek, CStone, customary, dashboard, Daurismo, deeply, depth, dialogue, District, donut, droit, elderly, embryonic, endorsement, exact, Excellence, excise, expedient, experimental, explicit, expressly, falsification, familiar, feature, gag, gaming, GDPR, HHS, hole, Hong, Iceland, impaneled, Importantly, inactivation, indefinitely, input, insert, inseverable, judge, Keytruda, Kong, laid, leakage, Liechtenstein, line, locked, lodge, lot, Macau, mainland, membership, misuse, mitapivat, modest, molecularly, monotherapy, month, multidisciplinary, Mylotarg, Northern, OCE, Opdivo, PA, Paediatric, Parliament, PDCO, penalty, perception, pertinent, pharmacy, pilot, pocket, practitioner, pre, predominant, presidential, PRIME, proactive, radiopharmaceutical, rapporteur, reassessment, referenda, relaxing, reprioritize, resell, restraining, RTOR, Rydapt, sNDA, SNO, sophisticated, speed, SSP, ST, straight, subcontractor, supervisory, supplementary, Supreme, Taiwan, Territory, TIBSOVO, TriCare, turnover, uncollectible, unfairly, unsatisfied, unsecured, upheld, vehicle, Venclexta, virtually, vorasidenib, Xospata, Yervoy
Removed:
Alexion, allocable, allogeneic, arising, aromatase, arrange, attach, bacterial, Calithera, carryback, certainty, concurrently, Conference, continuously, correction, CR, CRi, CRp, CRs, cytarabine, daunorubicin, deliverable, deterioration, diarrhea, discontinued, discounted, discretionary, doubtful, effusion, eleven, entail, equally, etoposide, eventually, expression, extending, febrile, fighting, finalize, footnote, founded, Genzyme, headcount, idarubicin, IEC, immature, incomplete, intrahepatic, IPAB, IPO, median, misleading, mission, mitoxantrone, moderate, MTD, mutating, neutropenia, owner, path, payroll, pervasive, platelet, PR, pretreatment, progressed, prolongation, QSR, QT, rationale, Raze, refundable, reinduction, relapse, remained, remit, retrospectively, Room, sampling, Sanofi, scale, Selvita, shelf, shipping, Shire, shut, SmPC, stable, steering, sublicense, tested, transferred, transplantation, unfair, unlock, unscheduled, untreated, vested, voucher, Washington, white, worthy
Filing tables
Filing exhibits
Related press release
Associated AGIO transcripts
AGIO similar filings
Filing view
External links
Exhibit 32.1
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with this Annual Report on Form 10-K of Agios Pharmaceuticals, Inc. (the “Company”) for the year ended December 31, 2018, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Jacqualyn Fouse, Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that, to her knowledge on the date hereof:
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
| February 14, 2019 | /s/ Jacqualyn A. Fouse | ||||
| Jacqualyn A. Fouse, Ph.D. | |||||
| Chief Executive Officer | |||||
| (principal executive officer) | |||||